| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GNAI3 |
| Uniprot No | P08754 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-354aa |
| 氨基酸序列 | GCTLSAEDKAAVERSKMIDRNLREDGEKAAKEVKLLLLGAGESGKSTIVK QMKIIHEDGYSEDECKQYKVVVYSNTIQSIIAIIRAMGRLKIDFGEAARA DDARQLFVLAGSAEEGVMTPELAGVIKRLWRDGGVQACFSRSREYQLNDS ASYYLNDLDRISQSNYIPTQQDVLRTRVKTTGIVETHFTFKDLYFKMFDV GGQRSERKKWIHCFEGVTAIIFCVALSDYDLVLAEDEEMNRMHESMKLFD SICNNKWFTETSIILFLNKKDLFEEKIKRSPLTICYPEYTGSNTYEEAAA YIQCQFEDLNRRKDTKEIYTHFTCATDTKNVQFVFDAVTDVIIKNNLKEC GLY |
| 预测分子量 | 42.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GNAI3重组蛋白的3篇模拟参考文献及其摘要概括：
---
1. **文献名称**：*"Recombinant Expression and Functional Characterization of GNAI3 in Bacterial Systems"*
**作者**：Chen L, Wang X, et al.
**摘要**：本研究报道了在大肠杆菌中成功表达并纯化具有生物活性的重组GNAI3蛋白，通过GTP结合实验验证其参与G蛋白信号通路的分子功能，为后续结构及药物筛选研究奠定基础。
2. **文献名称**：*"Structural Insights into GNAI3 Activation Mechanism via X-ray Crystallography"*
**作者**：Yamamoto K, Sato T, et al.
**摘要**：利用X射线晶体学解析了重组GNAI3蛋白的活化与非活化状态结构，揭示了其与Gβγ亚基及受体相互作用的关键位点，阐明了Gαi3在信号转导中的构象变化机制。
3. **文献名称**：*"Role of Recombinant GNAI3 in Modulating Cancer Cell Migration and Invasion"*
**作者**：Gupta R, Patel S, et al.
**摘要**：通过体外实验证明，重组GNAI3蛋白过表达可抑制RhoA信号通路，显著降低乳腺癌细胞的迁移和侵袭能力，提示其作为肿瘤治疗靶点的潜在价值。
---
以上文献方向涵盖重组蛋白表达、结构解析及功能应用，均为假设性示例，实际研究需通过学术数据库检索具体文献。
**Background of GNAI3 Recombinant Protein**
GNAI3 (G Protein Subunit Alpha I3) is a member of the inhibitory alpha subunit family of heterotrimeric G proteins, which play critical roles in transmitting signals from G protein-coupled receptors (GPCRs) to intracellular effectors. As part of the Gi/o subfamily, GNAI3 regulates downstream signaling pathways by inhibiting adenylate cyclase activity, reducing cAMP levels, and modulating ion channels or kinases such as MAPK and PI3K/Akt. This protein is broadly expressed in tissues and is involved in diverse cellular processes, including cell proliferation, differentiation, and migration. Dysregulation of GNAI3 has been linked to various diseases, such as cancer, immune disorders, and neurological conditions, highlighting its therapeutic and diagnostic potential.
Recombinant GNAI3 protein is produced using biotechnological methods, often through expression systems like *E. coli*, insect cells, or mammalian cells, followed by purification to ensure high purity and bioactivity. This engineered protein retains the functional domains of native GNAI3. enabling researchers to study its structure, interactions, and mechanistic roles *in vitro* or *in vivo*. It serves as a vital tool for investigating GPCR signaling cascades, screening drug candidates targeting G protein-related pathways, and identifying binding partners via assays like pull-down or co-immunoprecipitation.
Studies using recombinant GNAI3 have advanced our understanding of its oncogenic or tumor-suppressive roles in different cancers, including breast, liver, and colorectal malignancies. Additionally, it aids in exploring its involvement in immune cell regulation and synaptic transmission. The protein’s availability accelerates translational research, offering insights into disease mechanisms and paving the way for novel biomarkers or targeted therapies.
×
